NONPARTISAN · SOURCED FROM CONGRESS.GOV, OPENFEC, SENATE & HOUSE CLERKS · UPDATED REGULARLY
119th Congress · Senate bill · Last action Apr 10, 2025
BillsHealthS. 1414Congress.gov ↗
S. 1414In CommitteeHealth

Senate advances expedited pathway for biosimilar drug approvals

Sponsor: Sen. Paul, Rand (R-KY)2 cosponsorsIntroduced Apr 10, 2025
In plain English

A plain-English summary isn’t available for this bill yet.

Where it is in the process

Introduced
Apr 10
Senate committee
Apr 10
3
Senate floor
-
4
House
-
5
Signed
-
What happens next: Sits in committee. Needs a markup or favorable report to advance to the Senate floor.

Community vote

How readers of ThePolitibase feel about this bill. Reader sentiment only — not a scientific poll, and not a measure of public opinion.

- support · - oppose · - total

Sponsor

Cosponsors (2)

MS
MS
1 Democrat, 1 Republican (of 2 shown).

Activity timeline

Apr 10
Apr 10, 2025
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Apr 10
Apr 10, 2025
Introduced in Senate
Read the bill text
Official text via Congress.gov. Opens in a new tab.
Read full text →

Full action log

All 2 recorded actions since introduction · Source: Congress.gov
Apr 10
SENATERead twice and referred to the Committee on Health, Education, Labor, and Pensions.
Apr 10
Introduced in Senate

All 2 cosponsors

1 Democrat · 1 Republican
Democrats (1)
Republicans (1)

In the news

Holland & Knight Health Dose: July 21, 2026 - Holland & Knight
The FDA’s Biosimilar Burden—and How Congress Can Lift It - Cato Institute
The Evolving Cost-Benefit Landscape of Biosimilar Drug Development - BioPharm International
Karnataka Congress chief DK Shivakumar's wealth up 68% in 5 yrs, holds assets worth Rs 1,414 crore - Business Today
Track this bill
Get an alert when it moves to the next stage or gets a vote.
Share
Embed this tracker on your site
Paste this HTML into your blog post or website to show a live tracker for this bill.
The embedded card updates automatically as the bill progresses. Preview →